[1] Stone N N, Ramin SA, Wesson MF, et al. Laparoscopic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed prostate[J]. J Urol, 1995, 153:1555-1560.
[2] Blasko JC, Grimm PD, Ashley R, et al. Palladium-103 brachytherapy for prostate carcinoma[J]. Int J Radiat Oncol Biol Phys, 2000, 46(4):839-850.
[3] Sylvester J, Blasko JC, Grimm P, et al. Interstitial implantation techniques in prostate cancer[J]. J Surg Oncol, 1997, 66:65-75.
[4] Ling CC. Permanent implants using Au-198, Pd-103 and I-125:Radiobioligical considerations based on the linear quadratic model[J]. Int J Radiat Oncol Biol Phys, 1992, 23:81-87.
[5] Cha CM, Potters L, Ashley R, et al. Isotope selection for patients undergoing prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2):391-395.
[6] Wuu CS, Ennis RD, Schiff PB, et al. Dosimetric and volumetric criteria for selecting a source activity and a source type (125I or 103Pd) in the presence of irregular seed placement in permanent prostate implans[J]. Int J Radiat Oncol Biol Phys, 2000, 47(3):815-820.
[7] Blasko JC, Grimm PD, Ragde H, et al. Brachytherapy and organ preservation in the management of carcinoma of the prostate[J]. Semin Radiat Oncol, 1993, 3:240-249.
[8] Wallner K, Roy J, Harrion L, et al. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1995, 32:465-471.
[9] Anderson LL. Spacing nomograph for interstitial implants of I-125 seeds[J]. Med Phys, 1976, 3:48-51.
[10] Anderson LL, Moni JV, Harrion LB, et al. A nomograph for permanent implants of palladium-103 seeds[J]. Int J Radiat Oncol Biol Phys, 1993, 27:129-135.
[11] Yu Y, Waterman FM, Suntharalingam N, et al. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent 125I prostate implants[J]. Int J Radiat Oncol Biol Phys, 1996, 34:717-725.
[12] Anon. Consensus statement:guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel[J].Int J Radat Oncol Biol Phys, 1997, 37(5):1035-1041.
[13] Prestidge BR, Hoak DC, Grimm PD, et al. Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer[J]. Int J Radiat Oncol Biol Phys, 1997, 37:31-39.
[14] Ragde H, Korb LJ, Elgamal AA, et al. Modern Prostate Brachytherapy:prostate bpecific antigen results in 219 patients with up to 12 years of observed follow-up[J].Cancer, 2000, 89(1):135-141.
[15] Blasko JC. Brachytherapy[J]. Urology, 2000, 55:306-308.
[16] Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients:results from a single practice[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):111-117.
[17] D'Amico AV, Whittington R, Malkowicz SB, et al.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer[J]. JAMA, 1998, 280(11):969-974.
[18] Nori D, Mori J. Current issues in techniques of prostate brachytherapy[J]. Semin Surg Oncol, 1997, 13:444-453.
[19] Arterbery VE, Frazier A, Dalmia P, et al. Quality of life after permanent prostate implant[J]. Semin Surg Oncol, 1997, 13:461-464.
[20] Baird MC, Holt RW, Selby TL, et al. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy[J]. J Urol, 2000, 164:406-416.
[21] Whittington R, Broderick GA, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guide interstitial therapy for localized carcinoma of the prostate[J]. Int J Radiat Oncol Biol Phys, 1999, 44(5):1107-1110.